Compugen Ltd. (TLV:CGEN)
491.20
+3.20 (0.66%)
At close: Dec 25, 2025
Compugen Revenue
Compugen had revenue of $1.89M USD in the quarter ending September 30, 2025, a decrease of -88.96%. This brings the company's revenue in the last twelve months to $6.90M, down -88.47% year-over-year. In the year 2024, Compugen had annual revenue of $27.86M, down -16.72%.
Revenue (ttm)
$6.90M
Revenue Growth
-88.47%
P/S Ratio
20.14
Revenue / Employee
$93.28K
Employees
74
Market Cap
460.35M ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 27.86M | -5.60M | -16.72% |
| Dec 31, 2023 | 33.46M | 25.96M | 346.12% |
| Dec 31, 2022 | 7.50M | 1.50M | 25.00% |
| Dec 31, 2021 | 6.00M | 4.00M | 200.00% |
| Dec 31, 2020 | 2.00M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 17.80M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | 712.00K | -8.57M | -92.33% |
| Dec 31, 2015 | 9.28M | -3.09M | -24.99% |
| Dec 31, 2014 | 12.37M | 8.82M | 248.46% |
| Dec 31, 2013 | 3.55M | 3.31M | 1,366.53% |
| Dec 31, 2012 | 242.00K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | 1.12M | 865.00K | 346.00% |
| Dec 31, 2009 | 250.00K | -88.00K | -26.04% |
| Dec 31, 2008 | 338.00K | 158.00K | 87.78% |
| Dec 31, 2007 | 180.00K | -35.00K | -16.28% |
| Dec 31, 2006 | 215.00K | -431.00K | -66.72% |
| Dec 31, 2005 | 646.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 55.55B |
| Danel (Adir Yeoshua) | 2.87B |
| Novolog (Pharm-Up 1966) | 1.97B |
| Ilex Medical | 917.10M |
| Kamada | 578.74M |
| SofWave Medical | 255.13M |
| InterCure | 243.12M |
| BrainsWay | 162.56M |
Compugen News
- 10 days ago - Compugen rises on royalty deal with AstraZeneca - Seeking Alpha
- 10 days ago - AstraZeneca (AZN) and Compugen Partner to Monetize Royalties on Novel Therapy - GuruFocus
- 10 days ago - Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million - PRNewsWire
- 6 weeks ago - Compugen Ltd (CGEN) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
- 6 weeks ago - Q3 2025 Compugen Ltd Earnings Call Transcript - GuruFocus
- 6 weeks ago - Compugen Ltd. (CGEN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Compugen (CGEN) Reports Q3 Loss, Lags Revenue Estimates - Nasdaq
- 6 weeks ago - Compugen Reports Third Quarter 2025 Results - PRNewsWire